Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Shares of Oncothyreon Inc. Shot Up Today

By Brian Feroldi - Jun 1, 2015 at 1:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Oncothyreon stock was up big today. Is the movement meaningful, or just market noise?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Oncothyreon Inc (NASDAQ: ONTY), a biopharmaceutical company researching products for the treatment of cancer, was up more than 21% today after the company presented data at the American Society of Clinical Oncology 2015 meeting.

So what: The company presented positive data from their two ongoing clinical trials for ONT-380, an oral HER2 inhibitor designed to treat breast cancer. The first presentation highlighted positive data from a Phase 1b trial that combined ONT-380 with Xeloda and/or Herceptin as a third-line treatment. The company reported that ONT-380 was well tolerated and that 14 of the 27 patients in the trial showed either a complete or partial response to the therapy.

The second presentation highlighted positive data from another Phase 1b clinical trial related to the role that ONT-380 could play in the treatment of CNS metastases in combination with Kadcyla. Out of 14 patients, 5 showed either complete or partial response to the therapy, with the remainder showing a stable disease state.

Diana Hausman, M.D., Chief Medical Officer of Oncothyreon stated: "Oncothyreon is currently planning a blinded, randomized placebo-controlled Phase 2 trial of ONT-380 in combination with Herceptin and Xeloda for the treatment of HER2-positive metastatic breast cancer in patients who have failed both Perjeta (pertuzumab) and Kadcyla, which we expect to initiate late this year". 

Now what: Seeing positive news like this gave Oncothyreon investors a reason to cheer today, as it is always great when an investigational drug shows positive results that warrant further study. However, investors should remember that ONT-380 is only entering phase 2, and the drug still has many hurdles to clear before it could potentially become available. Oncothyreon remains a very high risk stock, as the company is still not generating any revenue and is losing money every year. Today's results are encouraging, but I'll personally be staying away until the company proves that it can get its drugs through the regulatory approval process and begin to generate meaningful revenue. Until then, the company is simply too high risk for my taste.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.